Clinical trials
Mesothelioma, Malignant trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
17 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2015 | 1 |
| 2017 | 1 |
| 2019 | 2 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 4 |
| 2024 | 4 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 8 |
| Recruiting | 5 |
| Active, not recruiting | 1 |
| Completed | 1 |
| Not yet recruiting | 1 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Ascentage Pharma Group Inc. | 1 |
| AstraZeneca | 1 |
| Beijing Biotech | 1 |
| Bristol-Myers Squibb | 1 |
| CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 1 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 1 |
| Capital Medical University | 1 |
| Chinese Academy of Medical Sciences | 1 |
| Chinese PLA General Hospital | 1 |
| ImmVira Pharma Co. Ltd | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Mesothelioma, Malignant | 17 |
| Ovarian Neoplasms | 4 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| Endometrial Neoplasms | 2 |
| Lymphoma | 2 |
| Mesothelioma | 2 |
| Neoplasm Metastasis | 2 |
| Neoplasms | 2 |
| Pancreatic Neoplasms | 2 |
| Triple Negative Breast Neoplasms | 2 |
Trials
Showing 76 to 17 of 17. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.